Temporal relationship with the clinical benefits of clopidogrel therapy
| Outcome |
CURE (clopidogrel) |
TRITON (prasugrel) |
TRILOGY (prasugrel) |
PLATO (ticagrelor) | Randomised controlled trial average |
Scotland 2006–2010 * (clopidogrel) |
| All-cause mortality | 5.8% | 3.0% | 8.3% | 4.5% | 5.40% | 25.4% |
| Cardiovascular death | 5.1% | 2.1% | 6.6% | 4.0% | 4.45% | 17.8% |
| Non-cardiovascular death | 0.7% | 0.9% | 1.7% | 0.5% | 0.95% | 7.6% |
| Fatal bleeding | 0.2% | 0.4% | 0.2% | 0.3% | 0.28% | 0.9% |
*From Information and Statistics Division of NHS Scotland.